In conclusion, we demonstrated that IL-21 engineered, CD19-specific CAR-NK cells showed enhanced anti-tumor efficacy against CD19+ lymphoma cells both in vitro and in vivo settings, as well as increased persistence in a mouse xenograft model of lymphoma compared to IL-15 engineered CAR-NK cells. This evidence concerns the gene CD19 and neoplasm.